
The Next Frontier of Microbiome Science
Probiotics aren't just for your gut anymore. But what exactly is microbiome science,
and how can gut microbes affect your immune and lung health?
Probiotics aren't just for your gut anymore. But what exactly is microbiome science,
and how can gut microbes affect your immune and lung health?
A proprietary combination of clinically studied probiotic strains and anti-inflammatory herbs, scientifically engineered to support lung structure and a healthy inflammatory response.*
From strain validation and product formulation to testing, we’re collaborating with leading scientists and research partners to develop the first microbiome-based nutritional interventions for lung health.
Founder & CEO
Chief Medical Officer
Director, Lab Operations
Advisor (Pediatric Lung Disease)
Endowed Professor & Virginia Walker Chair in Pediatrics, University of Alabama at Birmingham
Advisor (Microbiome, Adult Lung Disease)
Associate Professor, Pulmonary & Critical Care Medicine & Director Huang Microbiome Lab, University of Michigan
Advisor (Lung Transplant)
Assistant Professor Medical Director Lung Transplantation Program, Brigham & Women’s, Harvard University
Advisor (Gut-Lung Axis, Mycobiome)
Assistant Professor & Director, Willis Lung Lab, University of Alabama at Birmingham
Advisor (Clinical Trials, Adult Lung Disease)
Associate Professor, Pulmonary & Critical Care Medicine, University of Alabama at Birmingham
Advisor (Microbiome)
Professor Emeritus, Microbiome Resource Center & Cell Development & Integrative Biology, University of Alabama at Birmingham
Completed and ongoing studies of resB® Lung Support include
This was a randomized, open-label clinical trial in Cork, Ireland with healthy and asthmatic patients who took one resB® capsule twice daily (one in the morning, one at night) for one month.
Primary outcomes include testing safety measures. All participants tolerated the blend without adverse events.
Exploratory outcomes investigated changes in gut microbiota, serum MMP-9 and cytokines, CRP, lung function, oxygen levels, and changes in quality of life.
Completed 2022 – View Results
This is a multi-center randomized control trial in the United States with a dosing period of three months.
Primary outcomes center on change in quality of life.
Exploratory outcomes investigate clinical improvement markers (e.g., FEV1/FVC), gut and
lung microbiota, systemic and pulmonary biomarker changes (e.g., MMP-9, CRP,
cytokines, etc.)
This is a single-center randomized control trial in India with a dosing period of 14 days.
Primary outcomes center around pneumonia incidence and prognosis in elderly population in an acute care setting.
Your cart is currently empty.